Effect of Niacin on FGF23 Concentration in Chronic Kidney Disease | Zendy

Madhumathi Rao | Zendy; Michael W. Steffes | Zendy; Andrew G. Bostom | Zendy; Joachim H. Ix | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Niacin on FGF23 Concentration in Chronic Kidney Disease

Author(s) -

Madhumathi Rao,

Michael W. Steffes,

Andrew G. Bostom,

Joachim H. Ix

Publication year - 2014

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000362424

Subject(s) - medicine , placebo , hyperphosphatemia , niacin , kidney disease , endocrinology , dyslipidemia , renal function , gastroenterology , disease , alternative medicine , pathology

Elevated serum phosphorus and FGF23 are independent cardiovascular risk factors in patients with chronic kidney disease. In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research